# RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin

> **NCT00485342** · PHASE3 · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 236 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peg-interferon alpha 2a and ribavin
- **DRUG:** ribavirin with adaptation dose

## Key facts

- **NCT ID:** NCT00485342
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2012-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485342, "RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00485342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*